ArticleFrontiers in aging neuroscience2020
Assessment of Alzheimer's Disease Based on Texture Analysis of the Entorhinal Cortex.
Article in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Shape-Based Partially Linear Single-Index Cox Model for Alzheimer's Disease Conversion.Statistics in medicine · 2026Article
- Effects of a 5-week heart rate biofeedback randomized intervention on texture in the Alzheimer's Disease signature cortical region.Research square · 2026Article
- Associations between self-reported change in lifestyle behaviors and brain health: Findings from the Healthy Brain Initiative.Journal of Alzheimer's disease : JAD · 2026Article
- Cerebellar MRI-based radiomics models for identifying mild cognitive impairment: a retrospective multicenter study in Southeast China.Frontiers in aging neuroscience · 2025Article
- Effects of mixed metal exposures on MRI diffusion features in the medial temporal lobe.Neurotoxicology · 2024Article
- Effects of mixed metal exposures on MRI diffusion features in the medial temporal lobe.medRxiv : the preprint server for health sciences · 2024Article
- Neuroprotective Potential of Tannic Acid Against Neurotoxic Outputs of Monosodium Glutamate in Rat Cerebral Cortex.Neurotoxicity research · 2023Article
- An Optimized Deep Learning Model for Predicting Mild Cognitive Impairment Using Structural MRI.Sensors (Basel, Switzerland) · 2023Article
- Do radiomics or diffusion-tensor images provide additional information to predict brain amyloid-beta positivity?Scientific reports · 2023Article
- The Inflammatory GeneBiomedicines · 2023Article
- A cross-sectional study of explainable machine learning in Alzheimer's disease: diagnostic classification using MR radiomic features.Frontiers in aging neuroscience · 2023Article
- An integrative approach to dementia care.Frontiers in aging · 2023Review
- β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.Alzheimer's research & therapy · 2022Article
- Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis.Brain sciences · 2022Article
- Effect of APOE4 Allele and Gender on the Rate of Atrophy in the Hippocampus, Entorhinal Cortex, and Fusiform Gyrus in Alzheimer's Disease.Current Alzheimer research · 2022Article
- Behavioral and Psychological Symptoms of Dementia as a Means of Communication: Considerations for Reducing Stigma and Promoting Person-Centered Care.Frontiers in psychology · 2022Review
- Molecular mechanisms of neurodegeneration in the entorhinal cortex that underlie its selective vulnerability during the pathogenesis of Alzheimer's disease.Biology open · 2021Review
- Preserved Consciousness in Alzheimer's Disease and Other Dementias: Caregiver Awareness and Communication Strategies.Frontiers in psychology · 2021Review
- Amide Proton Transfer-Weighted MRI Might Help Distinguish Amnestic Mild Cognitive Impairment From a Normal Elderly Population.Frontiers in neurology · 2021Article
- Neuroimage Biomarker Identification of the Conversion of Mild Cognitive Impairment to Alzheimer's Disease.Frontiers in neuroscience · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's disease (AD) brain magnetic resonance imaging (MRI) biomarkers based on larger-scale tissue neurodegeneration changes, such as atrophy, are currently widely used. Texture analysis evaluates the statistical properties of the tissue image quantitatively; therefore, it could detect smaller-scale changes of neurodegeneration. Entorhinal cortex is the first region affected, and no study has investigated texture analysis on this region before. This study aims to differentiate AD patients from Normal Control (NC) and Mild Cognitive Impairment (MCI) subjects using entorhinal cortex texture features. Furthermore, it was evaluated whether texture has association to MCI beyond that of volume, to evaluate if atrophy development may precede. Texture features were extracted from 194 NC, 200 MCI, 84 MCI who converted to AD (MCIc), and 130 AD subjects. Receiving operating characteristic curves determined the performance of the various features in discriminating the groups, and a predictive model was used to predict conversion of MCIc subjects to AD. An area under the curve (AUC) of 0.872, 0.710, 0.730, and 0.764 was seen between NC vs. AD, NC vs. MCI, MCI vs. MCIc, and MCI vs. AD subjects, respectively. Including entorhinal cortex volume improved the AUCs to 0.914, 0.740, 0.756, and 0.780, respectively. For the disease prediction, binary logistic regression was applied on five randomly selected test groups and achieved on average AUC's of 0.760 and 0.764 on the training and validation cohorts, respectively. Entorhinal cortex texture features were significantly different between the four groups and in many cases provided better results compared to other methods such as volumetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.